AstraZeneca sues Lupin on Nexium (esomeprazole) patents

Swedish drug maker AstraZeneca has filed a lawsuit against India’s generic firm Lupin for allegedly violating its valid patents on its gastric reflux disease drug Nexium (esomeprazole magnesium delayed release capsules) though seeking to sell a generic version in US.

AstraZeneca has started legal proceedings against Lupin by filing a lawsuit in the district court of New Jersey alleging that Lupin’s abbreviated new drug application (ANDA) has infringed its United States Patent Nos. 5,714,504 (’504), 5,877,192 (’192), 6,875,872 (’872), 6,369,085 (’085), and 7,411,070 (’070).

Update: Lupin seeks US FDA approval for generic Glumetza; Depomed may sue for patent violation

Lupin has submitted an abbreviated new drug application designated ANDA No. 91-324 and Drug Master Files (DMF) seeking FDA’s approval to manufacture commercially esomeprazole magnesium delayed release capsules in 20 mg and 40 mg strengths under para IV certification.

Lupin’s ANDA seeking US FDA’a approval to commercially manufacture and use drugs which contain esomeprazole as active ingredient constitutes a violation because the patents ’504, ’192, ’872, ’085 and ’070 patents are still in force, AstraZeneca alleged in the lawsuit.

AstraZeneca’s ’504 patent entitled “Compositions,” was issued on February 3, 1998 to Astra Aktiebolag claims pharmaceutical formulations comprising alkaline salts of esomeprazole (including esomeprazole magnesium) and methods of using esomeprazole magnesium. The ’504 patent will expire on February 3, 2015 and pediatric exclusivity relating to the ’504 patent expires on August 3, 2015.

The ’192 patent,  refers to “Method For The Treatment Of Gastric Acid-Related Diseases And Production Of Medication Using (-)Enantiomer Of Omeprazole,” was issued on March 2, 1999 to Astra Aktiebolag, will expire on November 27, 2014. So is AstraZeneca’s ’872 patent, referring to esomeprazole magnesium is valid still November 27, 2014.

While AstraZeneca’s ’085 and ’070 patents have validity till November 25, 2018, the lawsuit claimed.

However, Lupin in the Notice of Certification under para IV, 21 U.S.C. Section 355(j)(2)(A)(vii), said that the ’504 patent, “is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted”

Nexium is currently one of the largest selling drugs in the world. Between the launch of esomeprazole in 2001 and 2005, Nexium has cloked AstraZeneca sales of about $14.4 billion.

Nexium is indicated for treatment of gastroesophageal reflux disease (GERD), healing of erosive esophagitis (EE).

Nexium 40 mg and Nexium 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed EE.

Nexium 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD.

Nexium is indicated for the short-term treatment (up to 8 weeks) of GERD (symptomatic GERD and healing of EE) in patients 1 to 17 years of age.